Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Research & Development: 2016-2024

Historic Research & Development for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $37.7 million.

  • Akebia Therapeutics' Research & Development rose 76.08% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.5 million, marking a year-over-year increase of 32.93%. This contributed to the annual value of $37.7 million for FY2024, which is 40.31% down from last year.
  • Per Akebia Therapeutics' latest filing, its Research & Development stood at $37.7 million for FY2024, which was down 40.31% from $63.1 million recorded in FY2023.
  • Over the past 5 years, Akebia Therapeutics' Research & Development peaked at $218.5 million during FY2020, and registered a low of $37.7 million during FY2024.
  • In the last 3 years, Akebia Therapeutics' Research & Development had a median value of $63.1 million in 2023 and averaged $76.9 million.
  • Data for Akebia Therapeutics' Research & Development shows a maximum YoY plummeted of 51.47% (in 2023) over the last 5 years.
  • Over the past 5 years, Akebia Therapeutics' Research & Development (Yearly) stood at $218.5 million in 2020, then tumbled by 32.33% to $147.9 million in 2021, then decreased by 12.08% to $130.0 million in 2022, then plummeted by 51.47% to $63.1 million in 2023, then plummeted by 40.31% to $37.7 million in 2024.